Seres Therapeutics, Inc. Additional Paid in Capital, Common Stock
Seres Therapeutics, Inc. (MCRB) had Additional Paid in Capital, Common Stock of $1.02 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-05
- 2026-06-30: Additional Paid in Capital, Common Stock $1.02B.
- 2026-03-31: Additional Paid in Capital, Common Stock $1.02B.
- 2025-12-31: Additional Paid in Capital, Common Stock $1.02B.
- 2025-09-30: Additional Paid in Capital, Common Stock $1.00B.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $1.02B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $1.02B 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $1.02B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $1.00B 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $998.21M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $995.87M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $991.87M 10-K · filed 2026-03-12 | $991.71M 10-K · filed 2025-03-13 |
| 2024-09-30 | $986.21M 10-Q · filed 2024-11-13 | |
| 2024-06-30 | $964.01M 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $958.48M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $933.24M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $921.74M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $911.62M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $887.68M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $875.18M 8-K · filed 2024-08-15 | |
| 2022-09-30 | $863.29M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $758.93M 10-Q · filed 2022-08-03 | |
| 2022-03-31 | $752.06M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $745.83M 10-K · filed 2023-03-07 | |
| 2021-09-30 | $739.99M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $733.53M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $727.87M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $723.48M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $718.48M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $434.59M 10-Q · filed 2020-07-28 | |
| 2020-03-31 | $417.82M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $411.25M 10-K · filed 2021-03-02 | |
| 2019-09-30 | $408.57M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $406.42M 10-Q · filed 2019-08-06 | |
| 2019-03-31 | $343.83M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $341.28M 10-K · filed 2020-03-02 | |
| 2018-09-30 | $337.49M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $332.87M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $328.45M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $324.38M 10-K · filed 2019-03-06 | |
| 2017-09-30 | $320.19M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $315.75M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $311.23M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $306.93M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $302.94M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $297.50M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $292.00M 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $287.94M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $285.15M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $143.22M 10-Q · filed 2015-08-10 | |
| 2014-12-31 | $1.10M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |